Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Íåâðîëîãèÿ è íåéðîõèðóðãèÿ

Íåâðîëîãèÿ è íåéðîõèðóðãèÿ Ôîðóìû: Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ, Ìàíóàëüíàÿ òåðàïèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 19.10.2003, 23:22
TatyanaKotova TatyanaKotova âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 18.03.2003
Ãîðîä: Ëåíèíãðàäñêàÿ îáë.
Ñîîáùåíèé: 5
TatyanaKotova *
çðèòåëüíûå íàðóøåíèÿ

â òå÷åíèè 5-6 ëåò, ïîñëå ðîæäåíèÿ ðåáåíêà, ó ìåíÿ íàáëþäàþòñÿ ñ ðàçëè÷íîé ïåðèîäè÷íîñòüþ ( îò ïîëóãîäà äî 2 ðàç â íåäåëþ) íàðóøåíèÿ çðåíèÿ â âèäå áëåñòÿùèõ ñâåòÿùèõñÿ çìååê ïåðåä ãëàçàìè â òå÷åíèè 5-40 ìèíóò. Ïîñëå êîòîðûõ íà÷èíàåòñÿ ãîëîâíàÿ áîëü. ïîñëåäíèé ìåñÿö ìåëüêàíèÿ ó÷àñòèëèñü, ÷óâñòâóþ óïàäîê ñèë, ãîëîâîêðóæåíèÿ (ïîøàòûâàíèÿ). Íà÷àëî ïðèñòóïîâ íè ñ ÷åì íå ñâÿçàíî. ïîñëå ïîñëåäíèõ ïðèñòóïîâ ãîëîâíûõ áîëåé íå áûëî. Äàâëåíèå îáû÷íî íîðìàëüíîå 110\80. ãåìîãëîáèí ïîíèæåí äî 85-90.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 20.10.2003, 14:49
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,442 ðàç(à) çà 31,785 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Òàòüÿíà!

Ñîîáùèòå ïîæàëóéñòà ïîëíûå äàííûå îáù.àíàëèçà êðîâè, âûïîëíåííîãî æåëàòåëüíî íà àâòîìàò. ñ÷åò÷èêå. Âàøè ïðîáëåìû ìîãóò áûòü ñâÿçàíû ñ àíåìèåé èëè äåôèöèòîì æåëåçà, íàïèøèòå òàêæå î ñîñòîÿíèè, âîëîñ, íîãòåé, ñî ñòîðîíû ñåðäöà, ÆÊÒ, âðåäíûå ïðèâû÷êè, ñîï. çàáîëåâàíèÿ, îáèëüíî ëè ìåíñòðóèðóåòå è ïð., ÷òî áåñïîêîèò Âàñ â òå÷åíèå ïîñëåäíèõ 5 ëåò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 20.10.2003, 20:33
TatyanaKotova TatyanaKotova âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 18.03.2003
Ãîðîä: Ëåíèíãðàäñêàÿ îáë.
Ñîîáùåíèé: 5
TatyanaKotova *
Çäðàâñòâóéòå! Ñïàñèáî, ÷òî îáðàòèëè âíèìàíèå íà ìîå ñîîáùåíèå. Äèàãíîç æåëåçîäåôè-öèòíàÿ àíåìèÿ ìíå ñòàâèëè ïîñëå ðîæäåíèÿ ïåðâîãî ðåáåíêà 14 ëåò íàçàä. Ïåðèîäè÷åñêè ïðèíèìàëà ôåððîïëåêñ, ôåððóìëåê, ôåíþëüñ. Ãåìîãëîáèí ïîâûøàëñÿ êðàòêîâðåìåííî äî 105-110. ïîñëåäíèé àíàëèç ïîëãîäà íàçàä ãåìîãëîáèí – 84, ýðèòðîöèòû – 3.0, öâ.ïîêàçàòåëü – 0,83, ðåòèêóëîöèòû – 11, òðîìáîöèòû (74:1000) 222,0 ëåéêîöèòû – 5,1 íåéòðîôèëû ñåãìåíòîÿäåðíûå 79 ëèìôîöèòû – 18 ìîíîöèòû –3 ÑÎÝ – 8 Îáùèé áåëîê – 70ã\ë, àëüáóìèíû – 50ã\ë, õîëåñòèðèí 3,4 Æåëåçî ñûâîðîòî÷íîå – 3,9 òîãäà æå ñäàëà àíàëèçû íà ãîðìîíû êðîâè Ò4 – 137, Ò3 – 3,2 , ÒÒà - 4,5 Íà âîëîñû è íîãòè æàëîá íåò. ÝÊà â íîðìå, õîòÿ ïåðèîäè÷åñêè áåñïîêîÿò ïîêàëûâàíèÿ â îáë .ñåðäöà. ñî ñòîðîíû ÆÊÒ æàëîá íåò , âðåäíûõ ïðèâû÷åê íåò. Ìåíñòðóàöèè îáèëüíûå (5-7 äíåé), ÷àñòî ñî ñãóñòêà-ìè. Ãèíåêîëîãè÷åñêèõ æàëîá íåò. Ïîñëåäíèå ãîäû áûñòðåå è ÷àùå óñòàþ, íóæäàþñü â äíåâíîì ñíå ( îêîëî 1 ÷àñà). Ãîëîâíûå áîëè ïî÷òè êàæäûé äåíü ðàçíîé èíòåíñèâíîñòè. Íî áîëüøå âñåãî âîëíóþò çðèòåëüíûå íàðóøåíèÿ, ò.ê. ìîÿ ðàáîòà òðåáóåò ïîñòîÿííîãî âíèìàíèÿ. Ñïàñèáî
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 21.10.2003, 11:38
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,442 ðàç(à) çà 31,785 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Òàòüÿíà!

 âàøåé ñèòóàöèè òàêòèêà ñëåäóþùàÿ: Âû ïðèîáðåòàåòå ñàìûé íåäîðîãîé ïðåïàðàò æåëåçà ñ ñîäåðæàíèåì ÈÎÍÍÎÃÎ æåëåçà â íåì ïðèìåðíî 60-100 ìã è ïðèíèìàåòå åãî íàòîùàê èç ðàñ÷åòà 1,5-2 ìã æåëåçà íà êã ìàññû òåëà, îäíîâðåìåííî ñ òàáëåòêàìè æåëåçà ïðèíèìàåòå 400-600 ìã âèòàìèíà Ñ. Ñòàðàåòåñü óâåëè÷èòü ïîòðåáëåíèå ìÿñà äî 100-150 ã â ñóòêè, ñíèçèòü - êðåïêèé ÷àé èëè êîôå. Âàø êóðñ ëå÷åíèÿ äîëæåí ñîñòàâëÿòü íå ìåíåå 4-6 ìåñ ñóììàðíî èëè íå ìåíåå 2-3 ìåñ åùå ïîñëå òîãî, êàê ãåìîãëîáèí ñòàíåò âûøå 120-125.
Äëÿ ñíèæåíèÿ èíòåíñèâíîñòè ôèç. êðîâîïîòåðü ïðè íàëè÷èè ïðåäìåíñòðóàëüíûõ áîëåé ìîæíî ïðèíèìàòü ïðîòèâîâîñïàëèòåëüíûå ïðåïàðàòû êàê íàïðîêñåí, äèêëîôåíàê èëè äð., åñëè áîëåé íåò, òî ìîæíî ïîïûòàòüñÿ ñ ìàëûõ äîç àíòèôèáðèíîëèòèêîâ- àìèíîêàïðîíîâîé êèñëîòû 0,5 ã 2-3 ðàñà â äåíü âî âðåìÿ öèêëà.
Ðàáîòîñïîñîáíîñòü, ïàìÿòü, êîíöåíòðàöèÿ âíèìàíèÿ ïîâûñÿòñÿ òîëüêî ïîñëå ïîëíîé êîððåêöèè æåëåçîäåôèöèòà â îðãàíèçìå (à íå ïðîñòî êîððåêöèè àíåìèè), òàêæå òîëüêî òîãäà ìîæíî îæèäàòü ñíèæåíèå èíòåíñèâíîñòè/ïðåêðàùåíèÿ ñîíëèâîñòè, ãîë. áîëåé, íàðóø. çðåíèÿ.
Òàê ÷òî, åñëè õîòèòå ïîâûñèòü êà÷åñòâî ñîáñòâåííîé æèçíè - íàáåðèòåñü òåðïåíèÿ è íà÷èíàéòå ëå÷èòüñÿ, áóäóò âîïðîñû - çàäàâàéòå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 28.10.2003, 22:51
TatyanaKotova TatyanaKotova âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 18.03.2003
Ãîðîä: Ëåíèíãðàäñêàÿ îáë.
Ñîîáùåíèé: 5
TatyanaKotova *
çäðàâñòâóéòå! íà÷àëà ïðèíèìàòü ñîáðèôåð äóðóëåñ, íî ó ìåíÿ îò ýòîãî ïðåïàðàòà òîøíîòà. ïîäñêàæèòå, ñòîèò ëè ïðèíèìàòü äàëüøå èëè ïîñîâåòóåòå çàìåíèòü åãî íà êàêîå-ëèáî äðóãîå ëåêàðñòâî. ñïàñèáî
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 29.10.2003, 15:05
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,442 ðàç(à) çà 31,785 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Òàòüÿíà!
Êàêóþ äîçó Ñîðáèôåðà âû ïüåòå, êîãäà (ó./â., äî/ïîñëå åäû), êàêóþ äîçó àñêîðáèíêè ïðèíèìàåòå (êîë. òàáëåòîê , äîçà â êàæäîé òàáëåòêå). Ïîæàëóéñòà ïîïîäðîáíåå êàê è êîãäà ïîÿâëÿåòñÿ òîøíîòà, òîãäà ìîæíî áóäåò ðåøèòü ñìîäóëèðîâàòü ëè âàì ïðèåì ñîðáèôåðà èëè ëó÷øå ïåðåéòè íà äðóãîé.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 29.10.2003, 20:00
TatyanaKotova TatyanaKotova âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 18.03.2003
Ãîðîä: Ëåíèíãðàäñêàÿ îáë.
Ñîîáùåíèé: 5
TatyanaKotova *
Çäðàâñòâóéòå, óâ. Dr.Vad. ñîðáèôåð ÿ ïðèíèìàþ 1 ðàç â ñóòêè ïî îäíîé òàáëåòêå çà 20-40 ìèíóò äî åäû. Òîøíîòà íàñòóïàåò ÷åðåç ÷àñ ïîñëå ïðèíÿòèÿ òàáëåòêè. Ïðîäîëæàåòñÿ 2-3 ÷àñà. Ïðîáîâàëà ïèòü óòðîì íàòîùàê , íî ïîòîì íà ðàáîòå òîøíèò. Ñåé÷àñ ïüþ ïåðåä óæèíîì. Òîøíèò òàêæå. Àñêîðáèíêó ïüþ 0,05 ïî 1 ò. 1 ðàç â äåíü. Îòäåëüíî îò ñîðáèôåðà.
Ñïàñèáî .
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 30.10.2003, 12:02
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,442 ðàç(à) çà 31,785 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Òàòüÿíà!

Ïîïðîáóéòå óâåëè÷èòü äîçó àñêîðáèíêè äî 10 òàáë çà 1 ðàç â ìîìåíò ïðèíÿòèÿ ñîðáèôåðà, åñëè áóäåò áåññîííèöà, íî òîøíîòû íå áóäåò, òî ïåðåíåñèòå íà óòðî èëè îáåä, òàêæå ìîæíî ïîïðîáîâàòü ïðèíèìàòü ïîñëå åäû ÷åðåç 1-1,5 ÷àñà.
Àñêîðáèíîâàÿ êèñëîòà óëó÷øàåò âñàñûâàíèå æåëåçà: ÷åì áîëüøå æåëåçà âñîñåòñÿ, òåì ìåíüøå ïîá. äåéñòâèå.
Åñëè âñå âûøåóêàçàííûå âàðèàíòû íå ïîäõîäÿò, òî àëüòåðíàòèâû ñëåäóþùèå
æåëåçà ôóìàðàò (õåôåðîë)
æåëåçà ãëþêîíàò (ôåððîíàë)
Íå âàæíî ñêîëüêî âåùåñòâà â òàáëåòêå, ãëàâíîå, ÷òî áû èîííîãî æåëåçà áûëî êàê ìèíèìóì 60-80 ìã íî íå áîëüøå 100 ìã (îñîáåííî åñëè Âàø âåñ 50-60 êã).
Áóäóò ïðîáëåìû, âîïðîñû - ïèøèòå, ãëàâíîå äëÿ Âàñ ïîäîáðàòü ïåðåíîñèìûé ïðåïàðàò è äîçó, ýòî îñíîâíîé çàëîã óñïåøíîãî ëå÷åíèÿ.
Êàê äóìàåòå ñíèæàòü îáèëèå ìåñÿ÷íûõ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 02.11.2003, 23:43
Tatiana Che
Ãîñòü
 
Ñîîáùåíèé: n/a
Óâ. Òàòüÿíà è ä-ð Âàäèì,

êîíå÷íî, ëå÷èòü àíåìèþ íóæíî, íî êóäà ýôôåêòèâíåå óñòðàíèòü åå ïðè÷èíó (ðåôåðåíñíûå çíà÷åíèÿ äëÿ ñûâîðîòî÷íîãî æåëåçà 8,95 - 30,43ìêìîëü/ë?). Ñàìàÿ î÷åâèäíàÿ ïðè÷èíà - íàðóøåíèÿ ìåíñòðóàëüíîãî öèêëà - ìåíîìåòðîððàãèÿ (ñãóñòêîâ â íîðìå íå äîëæíî áûòü âîîáùå). Êñòàòè, êàêèå íîðìàëüíûå çíà÷åíèÿ äëÿ ÒÒà â ëàáîðàòîðèè?


Òàòüÿíà, îïðåäåëèòüñÿ ñ ïðè÷èíîé ìåíîìåòðîððàãèè ïîìîæåò ÓÇÈ è èññëåäîâàíèå ôëîðû. È, åñëè ýòî íå âîåííàÿ òàéíà, ñêîëüêî Âàì ëåò?
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 03.11.2003, 12:28
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,442 ðàç(à) çà 31,785 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ äîêòîð Òàòüÿíà!

Ðåôåðåíòíûå çíà÷åíèÿ ïî æåëåçó ìîãóò áûòü è äðóãèå: íàïð. æ - 6.6-26 ìêÌ/ë, ì 11-28 ìêÌ/ë, íî è ýòî íå ïîêàçàòåëè íà êîòîðûå ñëåäóåò îïèðàòüñÿ - íàèáîëåå ÷óâñòâèòåëüíûì ÿâëÿåòñÿ êîýôôèöèåíò íàñûùåíèÿ òðàíñôåððèíà æåëåçîì: ÑÆ/ÎÆÑÑ è ìåíåå 25% ÿâëÿåòñÿ äåöèçèîííîé âåëè÷èíîé (åñëè íåò âîçìîæíîñòè îïðåäåëèòü ôåððèòèí, êîíå÷íî).
Êëèíè÷åñêèé ïðèìåð: ìóæ÷èíà ñûâ. Fe 12,5; OÆÑÑ 75, îáà ïîêàçàòåëÿ â ïðåäåëàõ ðåô. âåëè÷èí, êîýôô. 15%, ôåððèòèí 9.
Íå ñîãëàøóñü, ÷òî òîëüêî ÓÇÈ è ôëîðà îòâåòÿò íà âîïðîñ î ïðè÷èíå îáèëüíûõ ìåñÿ÷íûõ: èõ ïðè÷èíîé ìîãóò áûòü ñóáêëèíè÷åñêèé äåôèöèò ôàêòîðà ôîí Âèëëåáðàíäà, íàïð. åãî çíà÷åíèÿ â ïðåäåëàõ 55-75%, ÷òî íå äàåò òèïè÷íîé êëèíèêè áîëåçíè, à ïðîÿâëÿåòñÿ ëèøü èçáûòî÷íûìè ìåíñòðóàëüíûìè âûäåëåíèÿìè, ïðè îòñóòñòâèè ãèíåêîëîãè÷åñêèõ ïðè÷èí ó æåíùèí ñ îáèëüíûìè âûäåëåíèÿìè îáíàðóæèâàëàñü ïîâûøåííàÿ ôèáðèíîëèòè÷åñêàÿ àêòèâíîñòü â ìåíñòðóàëüíîé êðîâè è íàçíà÷åíèå àíòèôèáðèíîëèòèêîâ ñíèæàëî èõ îáèëüíîñòü â 2 ðàçà.
Âû âåðíî îòìåòèëè ïîâûøåíèå ÒÒà è íåêîòîðûìè ýíäîêðèíîëîãàìè ýòî ìîæåò áûòü ðàñöåíåíî êàê òí "ñóáêëèíè÷åñêèé ãèïîòèðåîç", ÷òî êñòàòè ÷åðåç ñíèæåíèå ñèíòåçà vWf ìîæåò óñèëèòü ìåíñòðóàëüíûå ïîòåðè êðîâè, íî â ðåêîìåíäàöèÿõ, íàñêîëüêî ìíå èçâåñòíî, íå ïîêàçàíà çàìåñòèò. ãîðì. òåðàïèÿ äëÿ êîððåêöèè ãèïåðìåíîððåè ïðè íîðìàëüíûõ çíà÷åíèÿõ Ò4.
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 05.11.2003, 01:13
Tatiana Che
Ãîñòü
 
Ñîîáùåíèé: n/a
Óâ. äîêòîð Âàäèì,

ÿ ïîíèìàþ Âàø èíòåðåñ ê äåôèöèòó ôàêòîðà ôîí Âèëëåáðàíäà, è ìíå ëè÷íî ýòî èíòåðåñíî òàêæå, íî, åñëè áëèæå ê ðåàëüíîé æèçíè: äåôåêò ôàêòîðà ôîí Âèëëåáðàíäà íàáëþäàåòñÿ ìåíåå, ÷åì ó 1% íàñåëåíèÿ (âêëþ÷àÿ è íåâûðàæåííûå ôîðìû - âåäü îá ýòîì ðå÷ü?), à ãèíåêîëîãè÷åñêèå çàáîëåâàíèÿ åñòü ïî÷òè ó 3/4 æåíùèí ñ ìåíîìåòðîððàãèåé (åñëè íå ÷àùå). È ÷åì æåíùèíà ñòàðøå, òåì âåðîÿòíîñòü ìèîìû è àäåíîìèîçà áîëüøå.
Åñëè ÒÒà ïðåâûøàåò íîðìó (ÿ áû çäåñü íå òîðîïèëàñü, íå ôàêò, ÷òî ýòî òàê) ïðè íîðìàëüíîì ñÒ4, íî íå áîëüøå 10 ìêåä/ë, òî ðå÷ü èäåò î ñ/ê ãèïîòèðåîçå, è î êîòîðîì, êàê ìèíèìóì, ñòîèò çíàòü Òàòüÿíå, ñîãëàñèòåñü, ìåíîìåòðîððàãèÿ - íå åäèíñòâåííàÿ ïðîáëåìà .
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 05.11.2003, 13:29
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,442 ðàç(à) çà 31,785 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ äîêòîð Òàòüÿíà!

Ñîãëàøóñü ñ Âàìè, ÷òî ãèíåêîëîãè÷åñêàÿ ïàòîëîãèÿ çàíèìàåò ëèäèðóþùåå ïîëîæåíèå â ãåíåçå ìåíîìåòðîððàãèè, ÿ æå èìåë â âèäó ïåðâè÷íûå (áåç íàëè÷èÿ ÿâíîé ãèíåêîëîãè÷åñêîé ïðè÷èíû).
Àðãóìåíòèðóþ îòâåò:

Blood Coagul Fibrinolysis. 2002 Mar;13(2):89-93.

von Willebrand's disease: an important cause of dysfunctional uterine bleeding.

Woo YL, White B, Corbally R, Byrne M, O'Connell N, O'Shea E, Sheppard BL, Bonnar J, Smith OP.

...VWD was diagnosed in five of 38 (13%) patients with menorrhagia and one of 38 (2.6%) patients with normal menstrual blood loss. The mean VWF:Ac value was significantly reduced in patients with menorrhagia (mean +/- standard deviation, 84.5 +/- 26.7 IU/dl versus 103.9 +/- 34.5 IU/dl; P < 0.01) and this effect persisted after exclusion of patients diagnosed with VWD...


J Thromb Haemost. 2003 Mar;1(3):477-84.

Platelet functional defects in women with unexplained menorrhagia.

Philipp CS, Dilley A, Miller CH, Evatt B, Baranwal A, Schwartz R, Bachmann G, Saidi P.

Menorrhagia is a common clinical problem and is unexplained in more than 50% of women... Seventy-four women were studied. Bleeding time was prolonged in 23 women (31.5%). Maximal percent platelet aggregation was decreased with one or more agonists in 35 (47.3%) women. The most commonly found platelet function defects were reduced aggregation responses to ristocetin in 22 (29.7%) women and to epinephrine in 16 women. Sixteen of 22 women with reduced ristocetin aggregation had von Willebrand ristocetin cofactor (VWF:RCo) and von Willebrand factor antigen (VWF:Ag) > 60%... Ten women (13.5%) had VWF:RCo and/or VWF:Ag < 60%.

Ò.å. ó êàæäîé òðåòüåé æåíùèíû ñ íåîáüÿñíèìîé ìåíîìåòðîððàãèåé ìîæíî íàéòè ñíèæåíèå ôàêòîðà ôîí Âèëëåáðàíäà, ó êàæäîé 7-8 îïðåäåëèòü çàáîëåâàíèå (ñíèæåíèå ìåíåå 60%). Õîòÿ îïÿòü-òàêè àïðèîðè ñîãëàøóñü, ÷òî ñðåäè âñåõ ìåíîìåòðîððàãèé äàííûé ïðîöåíò çíà÷èòåëüíî íèæå.

Beck EA, Limoni C.
Subnormal plasma von Willebrand factor (ristocetin cofactor) and iron deficiency anaemia in menstruating women.
Thromb Haemost. 1996 Apr;75(4):693.

Èíòåðåñíîå íàáëþäåíèå íàâîäèò íà ìûñëü, ÷òî âåðîÿòíî, ñàì ïî ñåáå æåëåçîäåôèöèò ìîæåò áûòü ïðè÷èíîé ñíèæåíèÿ ñèíòåçà/ñåêðåöèè ôô è ýòî â ñâîþ î÷åðåäü ìîæåò óñèëèâàòü ìåíñòðóàëüíûå ïîòåðè.

Ñðàâíèâàÿ 2 ðåôåðåíòíûõ äèàïàçîíà çíà÷åíèé ÒÒà (0,23 - 4,0 è 0,27 - 4,2 ìêU/ìë) ìîæíî çàêëþ÷èòü, ÷òî çíà÷åíèå 4,5 åñëè è íå ÿâëÿåòñÿ ïîâûøåííûì, òî ãðàíè÷èò ñ âåðõíåé ãðàíèöåé íîðìû ïðè èñïîëüçîâàíèè ëþáûõ òåñò-íàáîðîâ, íî ìåíÿ ýòî íå ñëèøêîì ñìóùàåò, òê åñòü íàáëþäåíèÿ, ÷òî ñóùåñòâóþò íåáîëüøèå èçìåíåíèÿ ãîðìîíîâ ÙÆ (ïîõîæèå íà èõ ñóáêëèíè÷åñêèé äåôèöèò) ïðè äåôèöèòå æåëåçà è ýòî ìîæåò íîðìàëèçîâàòüñÿ ïðè êîððåêöèè àíåìèè/äåôèöèòà æåëåçà.

Exp Clin Endocrinol Diabetes. 1999;107(6):356-60.

Incidence of sideropenia and effects of iron repletion treatment in women with subclinical hypothyroidism.

Duntas LH, Papanastasiou L, Mantzou E, Koutras DA.

Endocrine Unit, Evgenidion Hospital, Athens University Medical School, Greece.

Sideropenia affects ca. 20% of the world population, and iron dependent anemia is the most frequent type of anemia worldwide. The aim of the study was to investigate the incidence of sideropenia and dependent anemia in patients with subtle changes of the thyroid function, such as subclinical hypothyroidism (SH). 57 women with SH and 61 euthyroid controls (CG) were studied. Serum concentrations of T4, T3, TSH, anti-TPO, anti-Tg, ferrum (Fe), ferritin (Frt) total iron binding capacity (TIBC) and blood count were determined. In SH 17 patients (29.8%) presented low Fe levels (<50 microg/dl). 9 (15.7%) also had decreased Frt, confirming iron deficiency, whereas 8 patients presented additionally diminished hematocrit and hemoglobin levels, suggesting manifested sideropenic anemia. In CG, 10 persons (16%) had sideropenia, 6 (9.8%) had low Fe and Frt and only 3 (4.9%) had blood count alterations suggesting manifested sideropenic anemia. In SH, anti-TPO were positive in 39 patients (68%), whereas, in CG only 2 (3.2%) were positive. 8 patients with SH and manifested sideropenic anemia were treated with ironproteinsuccinylate (I-PSL), (80 mg Fe /day, for three months), a new iron compound. The repletion treatment safely led to the clinical and laboratory correction of sideropenia and showed a good tolerability. Furthermore, iron treatment provoked a minor increase of T4 and a mild decline of TSH, but the levels were not significant. These results suggest that sideropenia is a common finding in patients with slightly decreased thyroid activity, and that determination of Frt should be routinely advised. Finally, in the assessment of sideropenia and dependent anemia, evaluation of the thyroid function must be taken into account.
Îòâåòèòü ñ öèòèðîâàíèåì
  #13  
Ñòàðûé 08.11.2003, 22:10
NORA NORA âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 23.05.2003
Ãîðîä: Moscow
Ñîîáùåíèé: 16
NORA *
Î÷åíü èíòåðåñíàÿ äèñêóññèÿ! Íî ìíå õîòåëîñü áû îáðàòèòü âíèìàíèå íà ãîëîâíûå áîëè... Âîïðîñ ìèãðåíè. Óâàæàåìàÿ Òàòüÿíà, îïèøèòå Âàøè ãîëîâíûå áîëè - ãäå áîëèò, ìåíÿåòñÿ ëè ëîêàëèçàöèÿ ãîëîâíîé áîëè, êàêîâ õàðàêòåð ãîëîâíûõ áîëåé (òóïûå, íîþùèå, ðåçêèå, òÿíóùèå èëè èíûå), ñêîëüêî âðåìåíè äëèòñÿ êàæäûé ïðèñòóï ãîëîâíîé áîëè, íàñêîëüêî êàæäûé ýïèçîä îòëè÷àåòñÿ îò äðóãèõ, ñòðàäàëè ëè Âû ãîëîâíûìè áîëÿìè äî ðîäîâ, äî íà÷àëà ìåíñòðóàöèé, ïðîõîäèò ëè ãîëîâíàÿ áîëü ïðè ïðîãóëêå, ìîæåòå ëè Âû ðàáîòàòü ñ ãîëîâíîé áîëüþ, ðàçäðàæàåò ëè Âàñ ïðè ãîëîâíîé áîëè ñâåò, çâóêè. Ïîñëå òîãî êàê Âû ñòàëè ïðèíèìàòü ïðåïàðàò æåëåçà èçìåíèëèñü ëè Âàøè ãîëîâíûå áîëè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #14  
Ñòàðûé 12.11.2003, 22:48
Tatiana Che
Ãîñòü
 
Ñîîáùåíèé: n/a
óâàæàåìûé äîêòîð Âàäèì,

ãèïîòèðåîç/àíåìèÿ/ìåòðîððàãèÿ äîâîëüíî ñòàíäàðòíîå ñî÷åòàíèå, ÿ áû äàæå ñêàçàëà òàê, êëàññè÷åñêîå.
Íî ÷òîáû âîîáùå ïðåäìåòíî ãîâîðèòü î íàëè÷èè ñ/ê ãèïîòèðåîçà, íàäî èìåòü ðåçóëüòàò ïîâòîðíîãî îïðåäåëåíèÿ ÒÒÃ. È, ñîâñåì óæ â èäåàëå - çàêëþ÷åíèå óçè, ÷òî ïîçâîëèò õîòÿ áû ãðóáî îïðåäåëèòüñÿ, ÷òî òàì ñ ãèíåêîëîãè÷åñêèìè çàáîëåâàíèÿìè. Íå äóìàþ, ÷òî ýòà âîåííàÿ òàéíà íàì ïðèîòêðîåòñÿ, íî æåëàíèå çàãëÿäûâàòü â ðåçóëüòàòû áèîõèìè÷åñêèõ èññëåäîâàíèé ïðè ìåíîìåòðîððàãèè âñå æå ïðèâåòñòâóåòñÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 02:48.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.